Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Tumor cells evade immune detection by down-regulating antigen presentation and creating an immunosuppressive microenvironment.
• Tumor heterogeneity and genomic instability necessitate cancer vaccines with broad antigen coverage and rapid preparation.

Purpose of the Study:

• To develop a personalized whole tumor cell vaccine (TCV) platform, termed fragment autoantigens stimulated T-cell-immunotherapy (FAST), for effective cancer treatment.
• To evaluate the anti-tumor efficacy of FAST in preclinical cancer models and investigate its underlying mechanisms.

Main Methods:

• FAST involves rapid (7h) preparation of personalized fragmented antigens (FAs) from irradiated and cryoablated tumor cells.
• Preclinical studies utilized breast, colon, and melanoma mouse models to assess FAST's impact on tumor regression, metastasis, and survival.
• Mechanistic studies analyzed antigen presentation, immune microenvironment modulation, and FAST-associated protein value in clinical data.

Main Results:

• FAST demonstrated significant tumor regression, reduced metastasis, and prolonged survival in preclinical models.
• FAST outperformed other advanced TCVs, particularly in inhibiting metastasis.
• FAs enhanced antigen presentation via immunogenic cell death, MHC-I, and DAMPs, while reshaping the immune microenvironment to boost anti-tumor immunity.

Conclusions:

• FAST is a highly effective personalized TCV platform with significant anti-tumor efficacy, especially against metastasis.
• FAST-associated proteins hold prognostic and therapeutic value in various human cancers, including liver, stomach, rectal cancers, and melanoma.
• A clinical trial (NCT06756295) is initiating to further evaluate FAST's potential in cancer patients.